Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IMMU
- CUSIP: 45290710
- Web: www.immunomedics.com
Capitalization:- Market Cap: $1.56541 billion
- Outstanding Shares: 111,279,000
Average Prices:- 50 Day Moving Avg: $10.09
- 200 Day Moving Avg: $7.94
- 52 Week Range: $2.02 - $12.96
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -381.33
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $3.09 million
- Price / Sales: 411.98
- Book Value: ($0.53) per share
- Price / Book: -21.58
Profitability:- EBIDTA: ($71,330,000.00)
- Net Margins: -4,956.52%
- Return on Assets: -109.37%
Debt:- Debt-to-Equity Ratio: -1.65%
- Current Ratio: 1.29%
- Quick Ratio: 1.28%
Misc:- Average Volume: 2.57 million shs.
- Beta: 1.65
- Short Ratio: 19.33
Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 16th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.13. The business had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.75 million. The firm's revenue was down 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) EPS. View Immunomedics' Earnings History.
Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?
3 brokerages have issued 1-year price targets for Immunomedics' stock. Their predictions range from $14.00 to $15.00. On average, they expect Immunomedics' stock price to reach $14.50 in the next twelve months. View Analyst Ratings for Immunomedics.
Are investors shorting Immunomedics?
Immunomedics saw a increase in short interest in August. As of August 31st, there was short interest totalling 34,287,202 shares, an increase of 0.6% from the August 15th total of 34,074,923 shares. Based on an average trading volume of 4,662,516 shares, the days-to-cover ratio is presently 7.4 days. Approximately 34.4% of the shares of the company are short sold.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals Incorporated (LGND), Blueprint Medicines Corporation (BPMC), Sage Therapeutics (SAGE), Ironwood Pharmaceuticals (IRWD), Intrexon Corporation (XON), Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Esperion Therapeutics (ESPR), Global Blood Therapeutics (GBT), Genus plc (GNS), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT) and Albany Molecular Research (AMRI).
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Jason M. Aryeh, Chairman of the Board
- Cynthia L. Sullivan, President, Chief Executive Officer, Director
- Michael R. Garone, Chief Financial Officer, Vice President - Finance
- David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
- Geoffrey F. Cox Ph.D., Independent Director
- Robert Forrester, Independent Director
- Brian A. Markison, Lead Independent Director
- Bob Oliver, Independent Director
Who owns Immunomedics stock?
Immunomedics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (5.02%), State Street Corp (4.37%), Vanguard Group Inc. (4.13%), Farallon Capital Management LLC (3.83%), Palo Alto Investors LLC (2.73%) and First Light Asset Management LLC (1.86%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.
Who sold Immunomedics stock? Who is selling Immunomedics stock?
Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Chicago Equity Partners LLC, Virtu KCG Holdings LLC, First Light Asset Management LLC, Atlantic Trust Group LLC, UBS Asset Management Americas Inc., IFP Advisors Inc and Swiss National Bank. Company insiders that have sold Immunomedics stock in the last year include Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.
Who bought Immunomedics stock? Who is buying Immunomedics stock?
Immunomedics' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Palo Alto Investors LLC, State Street Corp, Lord Abbett & CO. LLC, Jennison Associates LLC, Goldman Sachs Group Inc., DAFNA Capital Management LLC and EAM Investors LLC. View Insider Buying and Selling for Immunomedics.
How do I buy Immunomedics stock?
Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of Immunomedics stock can currently be purchased for approximately $11.44.
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $14.50 (26.75% upside) |
Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/19/2017 | Jefferies Group LLC | Boost Price Target | Buy | $11.00 -> $14.00 | High |  |
| 7/24/2017 | Cowen and Company | Reiterated Rating | Outperform | $15.00 | Low | |
| 5/5/2017 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | | High | |
(Data available from 9/21/2015 forward)
Earnings History for Immunomedics (NASDAQ:IMMU)Earnings History by Quarter for Immunomedics (NASDAQ IMMU)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/16/2017 | Q4 2017 | ($0.12) | ($0.25) | $0.75 million | $0.64 million | View | N/A | |
| 2/9/2017 | Q2 2017 | ($0.13) | ($0.16) | $0.70 million | $0.38 million | View | Listen | |
| 11/2/2016 | Q117 | ($0.14) | ($0.17) | $0.70 million | $0.74 million | View | N/A | |
| 8/17/2016 | Q416 | ($0.11) | ($0.17) | $0.90 million | $0.93 million | View | Listen | |
| 5/4/2016 | Q3 | ($0.13) | ($0.15) | $0.70 million | $0.90 million | View | N/A | |
| 2/3/2016 | Q216 | ($0.14) | ($0.15) | $1.40 million | $0.67 million | View | N/A | |
| 11/4/2015 | Q116 | ($0.14) | ($0.16) | $1.23 million | $0.73 million | View | N/A | |
| 8/19/2015 | Q415 | ($0.13) | ($0.13) | $1.13 million | $2.40 million | View | Listen | |
| 5/6/2015 | Q3 2015 | ($0.13) | ($0.13) | $1.07 million | $1.18 million | View | N/A | |
| 2/4/2015 | Q215 | ($0.13) | ($0.12) | $1.73 million | $1.00 million | View | N/A | |
| 11/5/2014 | Q1 2015 | ($0.12) | ($0.13) | $1.18 million | $1.07 million | View | N/A | |
| 8/25/2014 | Q414 | ($0.13) | ($0.13) | $1.20 million | $1.20 million | View | N/A | |
| 5/7/2014 | Q3 2014 | ($0.12) | $0.02 | $1.13 million | $1.15 million | View | N/A | |
| 2/10/2014 | Q214 | ($0.10) | ($0.10) | $1.20 million | $1.20 million | View | N/A | |
| 8/22/2013 | Q4 2013 | ($0.12) | ($0.09) | $0.81 million | $1.40 million | View | N/A | |
| 5/8/2013 | Q3 2013 | ($0.10) | $0.11 | $0.97 million | $1.70 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Immunomedics (NASDAQ:IMMU)2017 EPS Consensus Estimate: ($0.53)
2018 EPS Consensus Estimate: ($0.56)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q2 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q3 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q4 2017 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q1 2018 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q2 2018 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q3 2018 | 1 | ($0.14) | ($0.14) | ($0.14) |
| Q4 2018 | 1 | ($0.19) | ($0.19) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 77.99%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/1/2017 | David M. Goldenberg | Insider | Sell | 20,000 | $12.64 | $252,800.00 | |
| 8/28/2017 | Cynthia L. Goldenberg | Director | Sell | 40,000 | $10.72 | $428,800.00 | |
| 8/23/2017 | Cynthia L. Goldenberg | Director | Sell | 40,000 | $9.24 | $369,600.00 | |
| 8/24/2016 | Don C Stark | Director | Sell | 9,900 | $2.97 | $29,403.00 | |
| 8/23/2016 | Mary E Paetzold | Director | Sell | 15,000 | $2.98 | $44,700.00 | |
| 6/13/2016 | Cynthia L Goldenberg | CEO | Sell | 371,990 | $3.03 | $1,127,129.70 | |
| 6/8/2016 | Cynthia L Goldenberg | CEO | Sell | 41,441 | $3.62 | $150,016.42 | |
| 6/8/2016 | David M Goldenberg | Chairman | Sell | 353,010 | $3.88 | $1,369,678.80 | |
| 6/7/2016 | Cynthia L Goldenberg | CEO | Sell | 4,600 | $4.01 | $18,446.00 | |
| 6/7/2016 | David M Goldenberg | Chairman | Sell | 12,300 | $3.98 | $48,954.00 | |
| 6/6/2016 | Cynthia L Goldenberg | CEO | Sell | 63,959 | $4.09 | $261,592.31 | |
| 6/6/2016 | David M Goldenberg | Chairman | Sell | 110,322 | $4.09 | $451,216.98 | |
| 6/15/2015 | David M Goldenberg | Chairman | Sell | 210,991 | $4.08 | $860,843.28 | |
| 6/12/2015 | Brian A Markison | Director | Sell | 5,564 | $4.22 | $23,480.08 | |
| 6/12/2015 | David M Goldenberg | Chairman | Sell | 359,653 | $4.32 | $1,553,700.96 | |
| 6/9/2015 | Mary E Paetzold | Director | Sell | 4,677 | $4.60 | $21,514.20 | |
| 6/5/2015 | Don C Stark | Director | Sell | 5,732 | $4.14 | $23,730.48 | |
| 12/11/2014 | Mary E Paetzold | Director | Sell | 10,000 | $4.71 | $47,100.00 | |
| 12/9/2014 | Don C Stark | Director | Sell | 5,500 | $4.51 | $24,805.00 | |
| 9/13/2013 | Don Stark | Director | Sell | 10,000 | $6.08 | $60,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Immunomedics (NASDAQ:IMMU)
Latest Headlines for Immunomedics (NASDAQ:IMMU)
| Source: |
|
| Date | Headline |
|---|
 | Jefferies Group Research Analysts Reduce Earnings Estimates for Immunomedics, Inc. (IMMU)
www.americanbankingnews.com - September 21 at 11:20 AM |
 | Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock
finance.yahoo.com - September 16 at 1:40 AM |
 | Immunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:28 AM |
| Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 13 at 2:53 PM |
 | BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i
www.reuters.com - September 12 at 1:39 AM |
| Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer
finance.yahoo.com - September 12 at 1:39 AM |
 | Immunomedics (IMMU) Reports Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) - StreetInsider.com
www.streetinsider.com - September 11 at 8:36 PM |
 | Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? - Nasdaq
www.nasdaq.com - September 11 at 8:36 PM |
| Immunomedics, Inc. (IMMU) Insider David M. Goldenberg Sells 20,000 Shares
www.americanbankingnews.com - September 5 at 10:26 PM |
| IMMU Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - September 1 at 8:13 PM |
| Immunomedics to Participate in Upcoming Investor Conferences
finance.yahoo.com - August 31 at 6:10 AM |
 | Immunomedics Stock Breaks Out, Consolidation Likely
www.investopedia.com - August 30 at 2:08 AM |
| Immunomedics, Inc. (IMMU) Director Sells $428,800.00 in Stock
www.americanbankingnews.com - August 28 at 10:22 PM |
| Immunomedics, Inc. (IMMU) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - August 28 at 8:44 PM |
| ETFs with exposure to Immunomedics, Inc. : August 28, 2017
finance.yahoo.com - August 28 at 7:28 PM |
 | Here's Why Immunomedics Rose as Much as 14.2% Today
www.fool.com - August 28 at 4:58 PM |
 | Mid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher
feeds.benzinga.com - August 28 at 12:52 PM |
| Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 7:05 AM |
| Mid-Afternoon Market Update: Crude Oil Down Over 2%; Abercrombie & Fitch Shares Surge Following Strong Q2 Results
feeds.benzinga.com - August 24 at 3:10 PM |
| Form 4 IMMUNOMEDICS INC For: Aug 21 Filed by: GOLDENBERG DAVID M
www.streetinsider.com - August 24 at 7:58 AM |
| Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017
finance.yahoo.com - August 24 at 7:58 AM |
| Immunomedics, Inc. (IMMU) Director Cynthia L. Goldenberg Sells 40,000 Shares
www.americanbankingnews.com - August 24 at 4:20 AM |
| BRIEF-Immunomedics announces publication of cancer drug data - Reuters
www.reuters.com - August 22 at 12:05 AM |
 | Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology
globenewswire.com - August 21 at 8:51 AM |
| Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer
finance.yahoo.com - August 21 at 8:51 AM |
| Immunomedics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.10) Per Share (IMMU)
www.americanbankingnews.com - August 21 at 6:22 AM |
| Immunomedics, Inc. (IMMU) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 19 at 12:52 PM |
| FY2022 EPS Estimates for Immunomedics, Inc. Cut by Analyst (IMMU)
www.americanbankingnews.com - August 18 at 2:28 PM |
| Immunomedics, Inc. (IMMU) PT Set at $11.00 by Jefferies Group LLC
www.americanbankingnews.com - August 18 at 11:22 AM |
| Immunomedics, Inc. (IMMU) Releases Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - August 17 at 9:20 AM |
| BRIEF-Immunomedics reports Q4 loss per share $0.48
www.reuters.com - August 17 at 5:54 AM |
| Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT
finance.yahoo.com - August 17 at 5:54 AM |
| Immunomedics' (IMMU) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 17 at 12:52 AM |
| Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : August 17, 2017
finance.yahoo.com - August 17 at 12:52 AM |
| After-Hours Earnings Report for August 16, 2017 : CSCO, NTAP, LB, VIPS, CACI, BGG, SPTN, IMMU, GPRK, PBIO - Nasdaq
www.nasdaq.com - August 16 at 7:49 PM |
| Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission ... - GlobeNewswire (press release)
globenewswire.com - August 16 at 7:49 PM |
| Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline
finance.yahoo.com - August 16 at 7:49 PM |
| Immunomedics reports 4Q loss
finance.yahoo.com - August 16 at 7:49 PM |
| Zacks Investment Research Lowers Immunomedics, Inc. (IMMU) to Hold
www.americanbankingnews.com - August 11 at 12:28 AM |
| Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results
finance.yahoo.com - August 7 at 7:15 PM |
| Immunomedics, Inc. (IMMU) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 4 at 11:52 PM |
| BRIEF-Immunomedics, Covance enter into master services agreement
www.reuters.com - August 4 at 8:07 PM |
| Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017
finance.yahoo.com - August 3 at 7:57 PM |
| Immunomedics, Inc. (IMMU) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 3:07 PM |
| Cowen and Company Reaffirms Outperform Rating for Immunomedics, Inc. (NASDAQ:IMMU)
www.americanbankingnews.com - July 24 at 4:10 PM |
| Immunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:56 AM |
| FY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group
www.americanbankingnews.com - July 17 at 11:11 AM |
| Jefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU)
www.americanbankingnews.com - July 15 at 4:12 PM |
| Jefferies Group Comments on Immunomedics, Inc.'s FY2022 Earnings (IMMU)
www.americanbankingnews.com - July 14 at 3:56 PM |
| Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers
finance.yahoo.com - July 10 at 7:51 PM |
Immunomedics (IMMU) Chart for Thursday, September, 21, 2017
